From Dr. Joseph Mercola Since COVID-19 first entered the scene, exchange of ideas has basically been outlawed. By sharing my views and those from various experts throughout the pandemic on COVID treatments and the experimental COVID jabs, I became a main target of the White House, the political establishment and the global cabal. Propaganda and… Read More »
Same-day initiation of antiretroviral therapy after diagnosis has some negative effects, including more patients lost to follow-up, according to a study conducted in Eswatini. The World Health Organization’s Treat-All policy recommends lifelong antiretroviral therapy (ART) for all people living with HIV at the time of diagnosis, irrespective of immunological criteria. Newly diagnosed individuals are generally… Read More »
Individuals with psychiatric disorders are at higher risk for obesity than the general population, as well as for medical comorbidity, such as diabetes, hypertension, hyperlipidemia, and cardiovascular disease. Because obesity is associated with an increased risk of adverse pregnancy outcomes, we examined the effect of obesity on neonatal and maternal outcomes in a group of… Read More »
Postpartum psychosis is the most severe form of postpartum psychiatric illness. It is a rare event that occurs in fewer than one out of every 1000 women after childbirth. Many women who have suffered from postpartum psychosis (PP) wonder about their long term prognosis. Will they have another psychotic episode if they have another child?… Read More »
Outcome prediction for heart failure patients based on routinely collected claims data was not significantly improved by using machine learning and information from electronic medical records. That’s the finding of a study published in the journal JAMA Network Open that compared machine learning with traditional models to predict heart failure. Specifically, investigators leveraged Medicare claims… Read More »
Now that AstraZeneca has scored its Farxiga outcomes data, it’s aiming to change the game on its SGLT2 diabetes rivals. First up? Expanding its salesforce to prepare for a full-court press on doctors. The British drugmaker aims to “increase the scope” of its physician marketing after phase 3 trial data showed Farxiga cut the risk of cardiovascular… Read More »
For women with bipolar disorder, choosing whether to maintain or discontinue treatment with a mood stabilizer during pregnancy is challenging. This is a process which requires careful and thoughtful consideration, weighing the risk of adverse outcomes associated with exposure to a particular drug against the risk of recurrent illness in the setting of medication discontinuation.… Read More »